|
Aurobindo Pharma
alpha-5-reductase inhibitor finasterid actavis/arcana/ Alpha 5 Reductase Inhibitor Finasterid Actavis/Arcana/, supplied by Aurobindo Pharma, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/inhibitor/alpha+5+reductase+inhibitor+finasterid+actavis+arcana+/nct06291675-32-13-16 Average 90 stars, based on 1 article reviews
alpha-5-reductase inhibitor finasterid actavis/arcana/ - by Bioz Stars,
2026-11
90/100 stars
|
Buy from Supplier |
|
Mendeley Ltd
topical calcineurin inhibitors Topical Calcineurin Inhibitors, supplied by Mendeley Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/inhibitor/calcineurin+inhibitors+topical/pm41949508-154-0-20 Average 86 stars, based on 1 article reviews
topical calcineurin inhibitors - by Bioz Stars,
2026-11
86/100 stars
|
Buy from Supplier |
|
MedChemExpress
dynamin related protein 1 drp1 inhibitor mdivi 1 ![]() Dynamin Related Protein 1 Drp1 Inhibitor Mdivi 1, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/inhibitor/Mdivi-1/pmc13054580-59-5-15 Average 99 stars, based on 1 article reviews
dynamin related protein 1 drp1 inhibitor mdivi 1 - by Bioz Stars,
2026-11
99/100 stars
|
Buy from Supplier |
|
Amgen
kras g12c covalent inhibitor ![]() Kras G12c Covalent Inhibitor, supplied by Amgen, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/inhibitor/sotorasib/pmc13019106-50-6-3 Average 86 stars, based on 1 article reviews
kras g12c covalent inhibitor - by Bioz Stars,
2026-11
86/100 stars
|
Buy from Supplier |
|
MedChemExpress
pgam5 inhibitor lfhp 1c ![]() Pgam5 Inhibitor Lfhp 1c, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/inhibitor/LFHP-1c/pmc13776596-50-1-7 Average 94 stars, based on 1 article reviews
pgam5 inhibitor lfhp 1c - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
Thermo Fisher
protease inhibitor cocktail ![]() Protease Inhibitor Cocktail, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/inhibitor/Protease+Inhibitor+Cocktail/pmc13772108-258-29-33 Average 99 stars, based on 1 article reviews
protease inhibitor cocktail - by Bioz Stars,
2026-11
99/100 stars
|
Buy from Supplier |
|
MedChemExpress
csd sirt5 inhibitor ![]() Csd Sirt5 Inhibitor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/inhibitor/SIRT5%2C+Human/pmc13774521-56-1-33 Average 94 stars, based on 1 article reviews
csd sirt5 inhibitor - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
Selleck Chemicals
g9a inhibitor bix 01294 ![]() G9a Inhibitor Bix 01294, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/inhibitor/BIX+01294/pmc13774038-264-40-48 Average 94 stars, based on 1 article reviews
g9a inhibitor bix 01294 - by Bioz Stars,
2026-11
94/100 stars
|
Buy from Supplier |
|
Thermo Fisher
phosphatase inhibitor cocktail ![]() Phosphatase Inhibitor Cocktail, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/inhibitor/Phosphatase+Inhibitor+Cocktail/pm43039902-181-15-18 Average 99 stars, based on 1 article reviews
phosphatase inhibitor cocktail - by Bioz Stars,
2026-11
99/100 stars
|
Buy from Supplier |
|
MedChemExpress
pi3kδ inhibitor cal 101 ![]() Pi3kδ Inhibitor Cal 101, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more https://www.bioz.com/product/inhibitor/Idelalisib/pmc13771831-217-14-17 Average 95 stars, based on 1 article reviews
pi3kδ inhibitor cal 101 - by Bioz Stars,
2026-11
95/100 stars
|
Buy from Supplier |
Journal: Military Medical Research
Article Title: USP18 exacerbates myocardial I/R injury by inhibiting Parkin mitophagy through the deubiquitinase PTEN-L
doi: 10.1016/j.mmr.2026.100004
Figure Lengend Snippet: USP18 aggravates cardiac I/R injury through regulation of mitochondria and inhibition of mitophagy. a Electron microscopy image showing mitophagy in USP18-cKO mouse hearts ( n= 5). Scale bar=3 μm. White arrowheads indicate sites of mitophagy. b Protein levels of PINK1, Parkin, ubiquitinated proteins (Ub), P62, and LC3II in mitochondria from heart tissue in USP18-cKO and WT mice 24 h after I/R injury ( n =4). c Electron microscopy image showing mitophagy in USP18-overexpres (OV) mouse hearts ( n =5). Scale bar=3 μm. White arrowheads indicate sites of mitophagy. d Protein levels of PINK1, Parkin, Ub, P62, and LC3II proteins in mitochondria from the heart tissue of USP18-OV mice 24 h after I/R injury ( n =4). Color shift in mitophagy dye (red) and lysosomal dye (green) in NRVMs showing mitophagy in NRVMs with USP18 siRNA transfection ( e ) or Ad-USP18 infection ( f ) and the quantitative mitophagy index in each group ( n= 5). Scale bar=9 μm. Protein levels of PINK1, Parkin, Ub, P62, and LC3II in mitochondria from NRVMs transfected with USP18 siRNA ( g ) or infected with Ad-USP18 ( h ). ⁎⁎ P <0.01, ⁎⁎⁎ P <0.001 ⁎⁎⁎⁎ P <0.0001. USP18. Ubiquitin-specific protease 18; I/R. Ischemia/reperfusion; WT. Wild-type; KO. Knockout; P62. Sequestosome 1; LC3. Microtubule-associated protein 1 light chain 3; VDAC. Voltage-dependent anion channel.
Article Snippet: To block mitophagy, the selective
Techniques: Inhibition, Electron Microscopy, Transfection, Infection, Ubiquitin Proteomics, Knock-Out
Journal: Pharmaceutical Science Advances
Article Title: Unleashing the power of DNA-encoded libraries for challenging targets in drug discovery
doi: 10.1016/j.pscia.2026.100115
Figure Lengend Snippet: Ligands targeting the GTPase KRAS G12C .
Article Snippet: In February 2025,
Techniques:
Journal: Journal of Medical Virology
Article Title: The Mitochondrial Phosphatase PGAM5 Restricts Hepatitis B Virus Replication via Phosphatase Activity
doi: 10.1002/jmv.71211
Figure Lengend Snippet: PGAM5L, but not PGAM5S, reduces the steady state levels of HBV RNAs (A) HepG2 cells were transfected with PAGM5‐expressing plasmids with viral promoter reporter plasmids (Sp1, Sp2, ENI/Xp and ENII/Cp). The relative fluorescence activity of Fluc relative to Rluc were determined. (B) HepG2 cells were transfected with rcccDNA plasmid system with or without plasmid overexpressing PGAM5. Actinomycin D was added 24 h post‐transfection. The decay kinetics of HBV pgRNA were monitored in a time‐course study. (C) Schematic presentation of PGAM5L and PGAM5S proteins and related mutations. (D) HepG2 cells were co‐transfected with rcccDNA plasmid system and different of PGAM5 isoforms and mutations, then the expression levels of HBsAg and HBeAg in the supernatants were determined. (E) The expression levels of HA‐tagged proteins were determined via Western Blot analysis. (F) HepG2 cells were transfected with viral ENI/Xp and ENII/Cp reporter plasmids and PGAM5 isoforms or mutations, then the relative fluorescence activity of Fluc relative to Rluc were determined. (G) HepG2 cells were transfected with prcccDNA+pCMV‐Cre or (H) pHBV1.3 plasmids, and treated with varying doses of LFHP‐1c. the expression levels of HBsAg and HBeAg in the supernatants were determined. Data were analyzed by one‐way ANOVA with Dunnett multiple comparison correction, and were presented as means ± SD. *indicates p < 0.05, **indicates p < 0.01, ***indicates p < 0.001.
Article Snippet: The
Techniques: Transfection, Expressing, Fluorescence, Activity Assay, Plasmid Preparation, Western Blot, Analysis, Comparison
Journal: Aging Cell
Article Title: FOXM1 Expression Enhances DNA Repair in Aged Cells to Maintain the Peripheral Heterochromatin Barrier Against Senescence Enhancers
doi: 10.1111/acel.70844
Figure Lengend Snippet: FOXM1 recovers G9a activity and H3K9me2 deposition at the nuclear periphery in aged cells by improving DNA repair. (a) Representative immunofluorescence images of G9a (green) and H3K9me2 (magenta) in young HDFs treated with either vehicle control (DMSO), etoposide (ETO) or ETO in the presence of MG132. (b) Quantification of G9a and H3K9me2 nuclear levels in young HDFs treated as mentioned in (a) ( n = 450 cells from 3 biological replicates per condition). (c) Representative images of G9a and H3K9me2 immunostainings in young versus aged HDFs. (d) Quantification of G9a and H3K9me2 nuclear levels in n = 900 cells from 3 biological replicates per age group. (e) Single‐cell correlation analysis between the fluorescence nuclear intensity levels of G9a and H3K9me2 in young and aged HDFs (see panels c, d). ρ = Spearman's rank correlation coefficient. (f) Representative confocal microscopy images of H3K9me2 (green‐fire‐blue gradient) and Lamin A/C (magenta) immunostainings in HDFs from donors grouped by age intervals as indicated (DNA in blue). (g, h) Quantification of the H3K9me2 peripheral/internal signal brightness (P/I) ratio (g) and percentage of H3K9me2 signal at the nuclear periphery (h) in HDFs ( n ≥ 122 cells obtained from 3 biological replicates in each age group). (i) Representative immunofluorescence images of G9a (green) and H3K9me2 (magenta) in young HDFs treated with mock versus FOXM1 RNAi. (j) Quantification of G9a and H3K9me2 nuclear levels in mock versus FOXM1 RNAi treated HDFs ( n = 1200 cells from 4 biological replicates per condition). (k) Immunofluorescence images of G9a (green) and H3K9me2 (magenta) in young or aged HDFs transduced with empty lentiviral vector or overexpressing FOXM1 (FOXM1 OE). (l) Quantification of G9a and H3K9me2 nuclear levels in HDFs as mentioned in (k) ( n = 1600 cells from 4 independent experiments using 2 biological samples). (m) Representative confocal microscopy images of H3K9me2 (green‐fire‐blue gradient) and Lamin A/C (magenta) immunostainings in aged HDFs overexpressing FOXM1 versus empty vector, in the presence of either DMSO or G9a inhibitor (BIX 01294). (n) Quantification of H3K9me2 nuclear levels in aged HDFs for the conditions mentioned in (m) ( n = 600 cells from 3 independent experiments using 2 biological samples). (o, p) Quantification of the H3K9me2 P/I ratio (o) and percentage of H3K9me2 signal at the nuclear periphery (p) in HDFs as mentioned in (m) ( n ≥ 45 cells from 3 biological replicates). Scale bars: 20 μm (a, c, i, k) or 5 μm (f, m). Statistics were performed using Kruskal–Wallis test with Dunn's multiple‐comparison correction (b, g, l, n), Mann–Whitney test (d, j), Spearman's rank correlation (e), and one‐way ANOVA test with Sidak's multiple‐comparison correction (h, o, p).
Article Snippet: To examine the influence of G9a activity in H3K9me2 recovery, aged HDFs transduced with the FOXM1‐dNdK transgene (versus empty vector) were treated with doxycycline for 72 h to stimulate ectopic FOXM1 expression, in the presence or absence of the specific
Techniques: Activity Assay, Immunofluorescence, Control, Single Cell, Analysis, Fluorescence, Confocal, Microscopy, Transduction, Plasmid Preparation, Comparison, MANN-WHITNEY
Journal: European Journal of Immunology
Article Title: The Phosphatidylinositol‐3‐Kinase δ‐Isoform Instructs Differentiation of Regulatory T‐Lymphocytes in the Thymus
doi: 10.1002/eji.70325
Figure Lengend Snippet: The catalytic activity of PI3Kδ favours intrathymic differentiation of PD‐1 + Treg. (A‐C) Thymic lobes from WT or PI3Kδ° E16 NOD foetuses were cultured for 4 days in the presence of titrated doses of PI3Kδ‐inhibitor CAL‐101 (IC 50 = 2.5 nM) and then analysed by flow cytometry. Results are from 4 independent experiments. (A) Quantification of Foxp3 + cells (Treg) among CD4 + CD8 − (CD4SP) TCRβ high thymocytes. (B) PD‐1 expression profiles of Foxp3 + Treg. (C) Quantification of PD‐1 + cells among Foxp3 + Treg, determined using the gate indicated in (B). (D–F) Rag2‐Gfp Foxp3‐Thy1 a NOD neonates of the indicated genotypes were intraperitoneally injected with the PI3Kδ inhibitor CAL‐101 every 12 h from day 0 to 4 of life. Results are from 3 independent experiments. (D) Quantification of Thy1.1 + cells (Treg) among GFP + (newly developed) CD4 + CD8 − (CD4SP) TCRβ high thymocytes. (E) Typical patterns of PD‐1 expression by newly developed Thy1.1 + Treg. (F). Quantification of PD‐1‐expressing cells among newly developed Thy1.1 + Treg. Dots represent individual cultured thymic lobes (A, C) or individual mice (D, F); bars indicate mean values ± SD. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001, **** p ≤ 0.0001, one‐way ANOVA with Dunnett's correction.
Article Snippet: WT or PI3Kδ° Rag2‐Gfp Foxp3‐Thy1 a NOD neonates were daily intraperitoneally injected with the
Techniques: Activity Assay, Cell Culture, Flow Cytometry, Expressing, Injection
Journal: European Journal of Immunology
Article Title: The Phosphatidylinositol‐3‐Kinase δ‐Isoform Instructs Differentiation of Regulatory T‐Lymphocytes in the Thymus
doi: 10.1002/eji.70325
Figure Lengend Snippet: PI3Kδ regulates intrathymic development of PD‐1 + Treg in a T‐cell intrinsic manner. (A‐C) FACS‐sorted PD‐1 − CD4SP thymocytes (gated PD‐1 − CD25 − Thy1.1 − GFP + TCRβ + CD8 − CD4 + ) were differentiated in vitro into Treg under anti‐CD3, anti‐CD28 and IL‐2 stimulation, in the presence of indicated concentrations of the PI3Kδ inhibitor CAL‐101. (A) Representative example of Thy1.1 (Foxp3) vs . CD25 expression by CD4SP cells after 2 days of culture, in the absence or presence of CAL‐101 (anti‐CD3 = 5 mg/mL). Percentages of cells within the gates are shown. (B) Proportions of differentiated (CD25 + Thy1.1 + ) Treg among live CD4SP cells. (C) Frequencies of PD‐1 + cells among CD25 + Thy1.1 + Treg. (D‐G) Lethally irradiated CD45.1 hosts that had received CD45.1/CD45.2 heterozygous WT control bone marrow plus CD45.2 WT or PI3Kδ° test bone marrow were analysed 6 weeks post‐reconstitution. (D) Typical CD45.1 vs . CD45.2 expression on thymocytes from these mixed chimaeras. (E) Proportions of newly developed Treg (Foxp3 + CCR7 + CD73 − ) among CD4 + CD8 − TCRβ high thymocytes of control and test bone‐marrow origin. (F) Typical PD‐1 expression profiles on newly developed Treg derived from control WT and test PI3Kδ° bone marrow. IMC, isotype‐matched control antibody. (G) Proportions of PD‐1 + cells among developing Treg derived from control and test bone marrow. In (B) and (C), dots represent means of three independent experiments, each performed on two individual mice ( n = 6); bars indicate mean values ± SEM. In (E) and (G), dots represent individual mice. ns: not significant, *** p ≤ 0.001, **** p ≤ 0.0001, two‐way ANOVA‐test with Bonferroni's correction.
Article Snippet: WT or PI3Kδ° Rag2‐Gfp Foxp3‐Thy1 a NOD neonates were daily intraperitoneally injected with the
Techniques: In Vitro, Expressing, Irradiation, Control, Derivative Assay
Journal: European Journal of Immunology
Article Title: The Phosphatidylinositol‐3‐Kinase δ‐Isoform Instructs Differentiation of Regulatory T‐Lymphocytes in the Thymus
doi: 10.1002/eji.70325
Figure Lengend Snippet: PI3Kδ controls the differentiation of highly autoreactive Treg into PD‐1 + cells. (A) Proportions and absolute numbers of developing Treg (Thy1.1 + GFP + TCRβ high CD4 + CD8 − ) in thymi from 4‐day‐old WT and PI3Kδ° Rag2‐Gfp Foxp3‐Thy1 a NOD neonates. (B) PD‐1 expression on newly developed Vβ3 + or Vβ8 + thymic Treg (Thy1.1 + GFP + TCRβ high CD4 + CD8 − ) (left), proportions of PD‐1 + cells among Vβ3 + or Vβ8 + Treg (right), gated as in the left panel. The percentage of cells within the indicated gate is shown. (C) Frequencies of Vβ3 + cells among Treg (Foxp3 + TCRβ high CD4 + CD8 − ) vs . proportions of PD‐1 + cells among Vβ3 + Treg. (D) Proportions of Vβ3 + cells among newly developed Treg in thymi from 4‐day‐old WT or PI3Kδ° NOD neonates, treated with the indicated twice‐daily doses of the PI3Kδ inhibitor CAL‐101 from days 0 to 4 of age. (E) Proportions of PD‐1 + cells among newly developed thymic Vβ3 + Treg from WT or PI3Kδ° NOD neonates, treated with the indicated doses of CAL‐101. Results are from 3 independent experiments (D, E). Dots represent individual mice; bars indicate mean values ± SD. ns: not significant, *** p ≤ 0.001, **** p ≤ 0.0001, two‐tailed Mann–Whitney test (A–C) or one‐way ANOVA with Dunnett's correction (D, E).
Article Snippet: WT or PI3Kδ° Rag2‐Gfp Foxp3‐Thy1 a NOD neonates were daily intraperitoneally injected with the
Techniques: Expressing, Two Tailed Test, MANN-WHITNEY
Journal: European Journal of Immunology
Article Title: The Phosphatidylinositol‐3‐Kinase δ‐Isoform Instructs Differentiation of Regulatory T‐Lymphocytes in the Thymus
doi: 10.1002/eji.70325
Figure Lengend Snippet: PI3Kδ instructs a specific identity during intrathymic Treg development. (A–F) RNA sequencing was performed on thymic CD25 + Thy1.1 + CD4 + CD8 − TCRβ high Tregs FACS‐sorted from 4‐day‐old WT (total, PD‐1 − and PD‐1 + Treg) or PI3Kδ° (total Treg) NOD neonates. (A) FC/FC plot of total PI3Kδ°/WT vs . PD‐1 − /PD‐1 + Treg (all annotated genes). (B) As in A, but for Treg‐signature genes only. (C) Principal component analysis of total, PD‐1 − and PD‐1 + WT Treg and total PI3Kδ° Treg transcriptomes. (D) Heatmap of PD‐1 + Treg transcriptomic signature (genes “up” in PD‐1 + vs . PD‐1 − WT Tregs) for total WT and PI3Kδ° Tregs. (E) Gene Set Enrichment Analysis (GSEA) was performed for selected transcriptomic signatures ( GSE7460 ) on WT vs . PI3Kδ° neonatal Thy1.1 + CD25 + TCRβ + CD4 + CD8 – Treg transcriptomes. (F) Heatmap of the relative expression of handpicked genes involved in Treg function (control of activity, suppressor effector functions) in PI3Kδ° vs . WT. (G–J) Expression of proteins involved in Treg function, as determined by flow cytometry. (G) Depicted are typical patterns of the expression of indicated markers by Foxp3 + CD4 + CD8 − TCRβ high Treg developing in the thymi of 4‐day‐old WT and PI3Kδ° mice. FMO: ‘fluorescence minus one’ controls. (H) MFI‐based heatmap of the analysis shown in (G). (I) Dimensional reduction analysis (OptSNE) of thymic Foxp3 + CD4 + CD8 − TCRβ high Treg based on expression of CD4, CD8, TCRβ, Foxp3, CD25, GITR, PD‐1, CD38, CD39, CD73, CTLA‐4, ICOS, Nrp1 and OX40. (J) gMFI of the expression of the indicated markers by Foxp3 + CD4 + CD8 − TCRβ high Treg that developed in WT NOD FTOC, cultured with (1 µM) or without PI3Kδ inhibitor CAL‐101. Results are from four independent experiments (J). Dots represent individual thymic lobes. ns: not significant, * p ≤ 0.05, *** p ≤ 0.001, **** p ≤ 0.0001, two‐tailed Mann–Whitney test.
Article Snippet: WT or PI3Kδ° Rag2‐Gfp Foxp3‐Thy1 a NOD neonates were daily intraperitoneally injected with the
Techniques: RNA Sequencing, Analysis, Gene Set Enrichment Analysis, Expressing, Control, Activity Assay, Flow Cytometry, Fluorescence, Cell Culture, Two Tailed Test, MANN-WHITNEY